Ripple’s stablecoin RLUSD has surged past a market value of $1.64 billion, securing its place among the world’s top 10 stablecoins. The growth comes amid a revival in risk appetite and renewed interest in the stablecoin segment across the cryptocurrency market.
RLUSD market value tops $1.64 billion with 72 percent surge
Trading volume and ranking climb in tandem
Data from SosoValue reveals that RLUSD reached the $1.64 billion market capitalization milestone for the first time, roughly one year after its launch. The past 24 hours saw trading volumes soar over 72 percent, fueling RLUSD’s rapid ascent. This move has elevated RLUSD to ninth place among stablecoins globally.
Further analysis shows that RLUSD has overtaken Tron-backed USDD in market capitalization. As a result, RLUSD’s advance signals renewed investor attention to stablecoins, positioning the asset as a leading example of shifting preferences in the sector.
RLUSD not only entered the global top 10 with a market value of over $1.64 billion during its first year, but a 72 percent jump in trading volume over the last 24 hours also underpinned its rise.
Institutional adoption and regulatory compliance driving growth
The article notes that RLUSD’s momentum is not only fueled by market trends but also by a growing range of institutional use cases. Designed for cross-border payments, the stablecoin is increasingly favored by organizations with international operations.
Ripple, the US-based financial technology company specializing in blockchain-powered payment solutions, is considered a key driver behind RLUSD’s development. The company’s ongoing partnerships and efforts to expand its ecosystem have played a pivotal role in the stablecoin’s surge.
RLUSD also differentiates itself on the regulatory landscape. Operating under the supervisory framework of the New York State Department of Financial Services (NYDFS) has reinforced the stablecoin’s credibility and compliance status.
RLUSD’s regulatory oversight and its expanding role in institutional cross-border transactions reflect growing acceptance within the digital asset ecosystem.
Market rebound fuels stablecoin ascent
RLUSD’s gains come as part of a broader rebound across the crypto market. After several months of weakness, renewed growth among major digital assets and stablecoins signals an improvement in investor sentiment across the sector.
This backdrop suggests that both payments providers and users seeking regulated blockchain-based solutions are increasingly drawn to RLUSD. Current data indicates that RLUSD’s rapid growth could become a pivotal force in reshaping the competitive dynamics of the stablecoin market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

